Antidepressant treatment outcomes of psychogenic movement disorder

Journal of Clinical Psychiatry

Volumn 66, Issue 12, 2005, Pages 1529-1534

  Voon, Valerie ^a,b   Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; PAROXETINE; VENLAFAXINE;

AGE DISTRIBUTION; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONVERSION DISORDER; DEPRESSION; DISEASE DURATION; DYSTONIA; FACTITIOUS DISEASE; GAIT DISORDER; GENERALIZED ANXIETY DISORDER; HUMAN; HYPOCHONDRIASIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTOR DYSFUNCTION; MYOCLONUS; OUTPATIENT CARE; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOGENIC MOVEMENT DISORDER; PSYCHOTHERAPY; REMISSION; SEX RATIO; SOCIAL PHOBIA; SOMATIZATION; SOMATOFORM DISORDER; SUBSTANCE ABUSE; TIC; TREMOR;

EID: 30344481984     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1206     Document Type: Article

References (27)

1. Williams DT, Ford B, Fahn S. Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol 1995;65:231-257
2. Stone J, Carson A, Sharpe M. Functional symptoms and signs in neurology: assessment and diagnosis. J Neurol Neurosurg Psychiatry 2005;76 (suppl 1):2-12
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association; 1994
4. Feinstein A, Stergiopoulos V, Fine J, et al. Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:169-176
5. Stone J, Sharpe M, Rothwell PM, et al. The 12 year prognosis of unilateral functional weakness and sensory disturbance. J Neurol Neurosurg Psychiatry 2003;74:591-596
6. Ron MA. The prognosis of hysteria/somatization disorder. In: Halligan PW, Bass C. Marshall JC, eds. Contemporary Approaches to the Study of Hysteria. New York, NY: Oxford University Press; 2001
7. Krem MM. Motor conversion disorders reviewed from a neuropsychiatric perspective. J Clin Psychiatry 2004;65:783-790
8. Ron M. Explaining the unexplained: understanding hysteria. Brain 2001;124:1065-1066
9. Cloninger C. The origins of DSM and ICD criteria for conversion and somatization disorders. In: Halligan PW, Bass C, Marshall JC, eds. Contemporary Approaches to the Study of Hysteria. New York, NY: Oxford University Press; 2001
10. Rowan AJ. Diagnosis of non-epileptic seizures. In: Gates JR, Rowan AJ, eds. Non-Epileptic Seizures. 2nd ed. Boston, Mass: Butterworth-Heinemann; 2000:15-30
11. Moene FC, Spinhoven P, Hoogduin KA, et al. A randomized controlled clinical trial of a hypnosis-based treatment for patients with conversion disorder, motor type. Int J Clin Exp Hypn 2003;51:29-50
12. Moene FC, Spinhoven P, Hoogduin KA, et al. A randomised controlled clinical trial on the additional effect of hypnosis in a comprehensive treatment programme for in-patients with conversion disorder of the motor type. Psychother Psychosom 2002;71:66-76
13. Rampello L, Raffaele R, Nicoletti G, et al. Hysterical neurosis of the conversion type: therapeutic activity of neuroleptics with different hyperprolactinemic potency. Neuropsychobiology 1996;33:186-188
14. Menza M, Lauritano M, Allen L, et al. Treatment of somatization disorder with nefazodone: a prospective, open-label study. Ann Clin Psychiatry 2001;13:153-158
15. O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999;48:980-990
16. Hurwitz TA. Somatization and conversion disorder. Can J Psychiatry 2004;49:172-178
17. Stone J, Carson A, Sharpe M. Functional symptoms in neurology: management. J Neurol Neurosurg Psychiatry 2005;76(suppl 1):13-21
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
19. Davidson J, Turnbull CD, Strickland R, et al. The Montgomery-Asberg Depression Scale: reliability and validity. Acta Psychiatr Scand 1986;73:544-548
20. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897
21. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health: 1976
22. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694-700
23. Crimlisk HL, Bhatia K, Cope H, et al. Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ 1998;316:582-586
24. Kienke AS, Rosenbaum JF. Efficacy of venlafaxine in the treatment of severe depression. Depress Anxiety 2000;12(suppl 1):50-54
25. Mallick R, Chen J, Entsuah AR, et al. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. J Clin Psychiatry 2003;64:321-330
26. Voon V. Treatment of psychogenic movement disorder: psychotropic medications. In: Hallett M, Fahn S, Jankovic J, et al, eds. Psychogenic Movement Disorders, Neurology and Neuropsychiatry. Neurology Reference Series. Philadelphia, Pa: Lippincott Williams and Wilkins; 2005:302-310
27. Voon V, Hallett M. Depression. In: Hallett M, Fahn S, Jankovic J, et al, eds. Psychogenic Movement Disorders, Neurology and Neuropsychiatry. Neurology Reference Series. Philadelphia, Pa: Lippincott Williams and Wilkins; 2005:148-153